Context Therapeutics (CNTX) Stock Price, News & Analysis

Company Overview

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens.

Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers. The company also maintains earlier-stage programs involving additional cancer targets.

Historically, Context Therapeutics focused on therapies for hormone-driven cancers, including development of selective progesterone receptor modulators, before shifting its primary emphasis toward T-cell-engaging antibody therapies. The company is based in Philadelphia, Pennsylvania, and its programs are being advanced through clinical and preclinical development for potential use in oncology markets.

Key Stats

• Today's Range: $0.19 to $0.22
• 50-Day Range: $0.19 to $0.39
• 52-Week Range: $0.18 to $3.62
• Volume: 1.35 million shs
• Average Volume: 1.56 million shs
• Market Capitalization: $19.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.40
• Consensus Rating: Moderate Buy

Context Therapeutics Stock Analysis - MarketRank™

Context Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 411th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Context Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Context Therapeutics has a consensus price target of $6.40, representing about 2,861.6% upside from its current price of $0.22.

Amount of Analyst Coverage

Context Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.42) per share.

Price to Book Value per Share Ratio

Context Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.37% of the float of Context Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Context Therapeutics has a short interest ratio ("days to cover") of 3.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Context Therapeutics has recently increased by 9.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Context Therapeutics does not currently pay a dividend.

Dividend Growth

Context Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.69

News Sentiment

Context Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Context Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Context Therapeutics is held by insiders.

Percentage Held by Institutions

14.03% of the stock of Context Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CNTX
• CIK: 1842952
• Web: www.contexttherapeutics.com
• Phone: 267-225-7416
• Fax: N/A
• Employees: 15
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Context Therapeutics: $6.40
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +2,861.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.29%
• Return on Assets: -75.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.81
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 91,879,000
• Free Float: 87,469,000
• Market Cap: $19.86 million
• Optionable: Not Optionable
• Beta: 1.77